108 related articles for article (PubMed ID: 1892368)
1. High-speed memory scanning in Parkinson's disease: adverse effects of levodopa.
Poewe W; Berger W; Benke T; Schelosky L
Ann Neurol; 1991 Jun; 29(6):670-3. PubMed ID: 1892368
[TBL] [Abstract][Full Text] [Related]
2. Dopaminergic effects on cognitive performance in patients with Parkinson's disease.
Lange KW; Paul GM; Naumann M; Gsell W
J Neural Transm Suppl; 1995; 46():423-32. PubMed ID: 8821078
[TBL] [Abstract][Full Text] [Related]
3. Dopamine and memory function in Parkinson's disease.
Mohr E; Fabbrini G; Williams J; Schlegel J; Cox C; Fedio P; Chase TN
Mov Disord; 1989; 4(2):113-20. PubMed ID: 2543918
[TBL] [Abstract][Full Text] [Related]
4. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
[TBL] [Abstract][Full Text] [Related]
5. Levodopa improves time-based prospective memory in Parkinson's disease.
Costa A; Peppe A; Brusa L; Caltagirone C; Gatto I; Carlesimo GA
J Int Neuropsychol Soc; 2008 Jul; 14(4):601-10. PubMed ID: 18577289
[TBL] [Abstract][Full Text] [Related]
6. Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease.
Lewis SJ; Slabosz A; Robbins TW; Barker RA; Owen AM
Neuropsychologia; 2005; 43(6):823-32. PubMed ID: 15716155
[TBL] [Abstract][Full Text] [Related]
7. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease.
Funkiewiez A; Ardouin C; Krack P; Fraix V; Van Blercom N; Xie J; Moro E; Benabid AL; Pollak P
Mov Disord; 2003 May; 18(5):524-30. PubMed ID: 12722166
[TBL] [Abstract][Full Text] [Related]
8. Cholinergic deficiency and frontal dysfunction in Parkinson's disease.
Dubois B; Pilon B; Lhermitte F; Agid Y
Ann Neurol; 1990 Aug; 28(2):117-21. PubMed ID: 2221841
[TBL] [Abstract][Full Text] [Related]
9. Motor program memory storage in Parkinson's disease patients tested with a delayed response task.
Labutta RJ; Miles RB; Sanes JN; Hallett M
Mov Disord; 1994 Mar; 9(2):218-22. PubMed ID: 8196687
[TBL] [Abstract][Full Text] [Related]
10. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
[TBL] [Abstract][Full Text] [Related]
11. Deficit of short-term memory in newly diagnosed untreated parkinsonian patients: reversal after L-dopa therapy.
Marini P; Ramat S; Ginestroni A; Paganini M
Neurol Sci; 2003 Oct; 24(3):184-5. PubMed ID: 14598078
[TBL] [Abstract][Full Text] [Related]
12. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.
Fera F; Nicoletti G; Cerasa A; Romeo N; Gallo O; Gioia MC; Arabia G; Pugliese P; Zappia M; Quattrone A
Brain Res Bull; 2007 Sep; 74(1-3):75-83. PubMed ID: 17683792
[TBL] [Abstract][Full Text] [Related]
13. Effects of Parkinson's disease and dopamine on digit span measures of working memory.
Grogan JP; Knight LE; Smith L; Irigoras Izagirre N; Howat A; Knight BE; Bickerton A; Isotalus HK; Coulthard EJ
Psychopharmacology (Berl); 2018 Dec; 235(12):3443-3450. PubMed ID: 30315362
[TBL] [Abstract][Full Text] [Related]
14. [Memory changes in Parkinson's disease. Relation with clinical variables].
Bruna O; Junqué C; Vendrell P; Roig C; Grau-Veciana JM
Neurologia; 1992 Feb; 7(2):55-60. PubMed ID: 1610601
[TBL] [Abstract][Full Text] [Related]
15. Incidental and intentional recall in Parkinson's disease: an account based on diminished attentional resources.
Cooper JA; Sagar HJ
J Clin Exp Neuropsychol; 1993 Sep; 15(5):713-31. PubMed ID: 8276931
[TBL] [Abstract][Full Text] [Related]
16. Effects of levodopa on corticostriatal circuits supporting working memory in Parkinson's disease.
Simioni AC; Dagher A; Fellows LK
Cortex; 2017 Aug; 93():193-205. PubMed ID: 28675834
[TBL] [Abstract][Full Text] [Related]
17. Abnormal excitability of premotor-motor connections in de novo Parkinson's disease.
Buhmann C; Gorsler A; Bäumer T; Hidding U; Demiralay C; Hinkelmann K; Weiller C; Siebner HR; Münchau A
Brain; 2004 Dec; 127(Pt 12):2732-46. PubMed ID: 15509619
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Parkinson's disease: levodopa as the first choice.
Katzenschlager R; Lees AJ
J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
[TBL] [Abstract][Full Text] [Related]
19. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease.
Mouradian MM; Heuser IJ; Baronti F; Chase TN
Ann Neurol; 1990 Jan; 27(1):18-23. PubMed ID: 2301923
[TBL] [Abstract][Full Text] [Related]
20. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
Kondo T
J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
